Business
Sierra Oncology Q3 2018 Results
Sierra Oncology Q3 2018 Results.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8061G Sareum Holdings PLC 08 November 2018 \n\n(AIM: SAR) 8 November 2018\n \nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSareum notes Sierra Oncology has reported Third Quarter 2018 Results\n \nSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has reported its Third Quarter 2018 Results including reference to the ongoing development of SRA737.\n \nIn the statement, Sierra CEO Nick Glover commented that Sierra has made substantial progress enrolling genetically-selected patients into the indication-specific cohorts of two SRA737 trials, with a focus on recruiting patients with High Grade Serous Ovarian Cancer (HGSOC). Preliminary efficacy results from these trials are expected to be reported in the first half of 2019. \n \nSierra has also continued preparing for the initiation of a Phase 1b/2 trial of SRA737 with the PARP inhibitor niraparib, which will evaluate this combination in subjects with metastatic castration-resistant prostate cancer (mCRPC).\n \nTitle of announcement: Sierra Oncology Reports Third Quarter 2018 Results\n \nLink to announcement: https://www.prnewswire.com/news-releases/sierra-oncology-reports-third-quarter-results-300744943.html \n \nFor further information, please contact: \n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nomin...